Literature DB >> 24344498

Urothelial dysplasia of the bladder: diagnostic features and clinical significance.

Antonio Lopez-Beltran1, Rodolfo Montironi2, Alfredo Vidal3, Marina Scarpelli2, Liang Cheng4.   

Abstract

The 2004 World Health Organization classification system for urothelial neoplasia identifies urothelial dysplasia (low-grade intraurothelial neoplasia) as a premalignant lesion of the urothelium. Although diagnostic criteria of urothelial dysplasia have been improved in recent years, there is a frequent lack of interobserver reproducibility. Follow-up studies suggest that dysplasia is a marker for urothelial instability and disease progression in up to 19% of patients, thus supporting an active clinical follow-up in these patients. The main differential diagnosis of urothelial dysplasia includes flat urothelial lesions with atypia, mainly flat (simple) urothelial hyperplasia, reactive urothelial atypia, urothelial atypia of unknown significance, and urothelial carcinoma in situ (high-grade intraurothelial neoplasia). In most cases, morphologic features alone suffice for diagnosis. Some cases may require a panel of immunohistochemical antibodies consisting of cytokeratin 20, p53 and CD44 for diagnosis. We present pathologic features and clinical significance of urothelial dysplasia with emphasis on differential diagnosis from common flat urothelial lesions with atypia.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24344498

Source DB:  PubMed          Journal:  Anal Quant Cytopathol Histpathol        ISSN: 2578-742X


  7 in total

Review 1.  Ketamine-induced urological toxicity: potential mechanisms and translation for adults with mood disorders receiving ketamine treatment.

Authors:  Jason Ng; Leanna M W Lui; Joshua D Rosenblat; Kayla M Teopiz; Orly Lipsitz; Danielle S Cha; Jiaqi Xiong; Flora Nasri; Yena Lee; Kevin Kratiuk; Nelson B Rodrigues; Hartej Gill; Mehala Subramaniapillai; Rodrigo B Mansur; Roger Ho; Bing Cao; Roger S McIntyre
Journal:  Psychopharmacology (Berl)       Date:  2021-01-23       Impact factor: 4.530

2.  Bladder cancer: Normal cystoscopy, malignant cytology in NMIBC: why biopsy?

Authors:  Antonio Lopez-Beltran
Journal:  Nat Rev Urol       Date:  2014-08-26       Impact factor: 14.432

Review 3.  Evolution of Premalignant Disease.

Authors:  Kit Curtius; Nicholas A Wright; Trevor A Graham
Journal:  Cold Spring Harb Perspect Med       Date:  2017-12-01       Impact factor: 6.915

Review 4.  Biomarkers for bladder cancer management: present and future.

Authors:  Fei Ye; Li Wang; Mireia Castillo-Martin; Russell McBride; Matthew D Galsky; Jun Zhu; Paolo Boffetta; David Y Zhang; Carlos Cordon-Cardo
Journal:  Am J Clin Exp Urol       Date:  2014-04-05

5.  Oncogenic HRAS Activates Epithelial-to-Mesenchymal Transition and Confers Stemness to p53-Deficient Urothelial Cells to Drive Muscle Invasion of Basal Subtype Carcinomas.

Authors:  Feng He; Jonathan Melamed; Moon-Shong Tang; Chuanshu Huang; Xue-Ru Wu
Journal:  Cancer Res       Date:  2015-03-20       Impact factor: 12.701

6.  Dysplastic urothelial changes accompany empagliflozin administration in urinary bladder of experimental diabetes.

Authors:  Ahmed A M Abdel-Hamid; Alaa El-Din L Firgany
Journal:  Int J Exp Pathol       Date:  2020-02-10       Impact factor: 1.925

7.  p-Benzoquinone initiates non-invasive urothelial cancer through aberrant tyrosine phosphorylation of EGFR, MAP kinase activation and cell cycle deregulation: Prevention by vitamin C.

Authors:  Shinjini Ganguly; Ayan Chandra; Dhruba J Chattopadhyay; Indu B Chatterjee
Journal:  Toxicol Rep       Date:  2017-06-15
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.